<DOC>
	<DOCNO>NCT00744770</DOCNO>
	<brief_summary>The purpose Phase I , open-label , single-sequence drug-drug interaction trial patient stable methadone maintenance therapy investigate potential interaction TMC278 25 mg daily methadone , steady-state .</brief_summary>
	<brief_title>TMC278-TiDP6-C121 : Drug-drug Interaction Trial Investigate Potential Interaction Between TMC278 25 mg Daily Methadone , Steady State .</brief_title>
	<detailed_description>This Phase I , open-label , single-sequence drug-drug interaction trial patient stable methadone maintenance therapy , investigate potential interaction TMC278 25 mg daily methadone , steady-state . TMC278 development treatment HIV-1 infect patient . The trial population consist 16 HIV-negative patient stable methadone maintenance therapy . Patients receive TMC278 25 mg daily 11 day , add current methadone therapy . The current methadone dosage patient change screen Day 11 inclusive . Methadone dose individualized patient 60 150 mg daily . Full 24 hour pharmacokinetic profile R- S-methadone determine Day -1 ( methadone alone ) Day 11 ( methadone + TMC278 ) . A full 24 hour pharmacokinetic profile TMC278 determine Day 11 ( methadone + TMC278 ) . Pharmacodynamic assessment symptoms methadone withdrawal ( Short Opiate Withdrawal Scale ( SOWS ) , Desires Drugs Questionnaire ( DDQ ) , pupillometry ) perform Day -7 daily Day -3 Day 11 , within 2 hour intake methadone . Safety tolerability evaluate continuously throughout trial . Patients receive TMC278 add current methadone therapy follow way : methadone individualized maintenance therapy , 60 150 mg daily Day -14 11 TMC278 25 mg tablet mouth daily Day 1 11 . TMC278 methadone take within 10 minute completion breakfast .</detailed_description>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Body Mass Index 18.0 30.0 kg/m2 , extremes include Receiving daily oral methadone maintenance therapy stable individualize dose 60 150 mg The patient agree change current methadone dose screen Day 11 include daily observe document methadone intake Day 14 Day 12 , daily observe document TMC278 intake Day 1 Day 11 Able comply protocol requirement The patient obtain approval his/her addiction physician participation trial . Furthermore , addiction physician agree provide medical care patient discharge test facility General medical condition , investigator 's opinion , interfere assessment completion trial Otherwise healthy basis physical examination , medical history ( except drug abuse ) , ECG , vital sign result blood biochemistry hematology test urinalysis carry screening . A positive test HIV1 , HIV2 , hepatitis A virus hepatitis B virus female child bear potential evidence current use illicit drug opioids ( exception methadone ) abuse alcohol impair liver function define protocol currently active underlie disorder , include gastrointestinal , cardiovascular , neurologic , psychiatric ( drug dependency ) , metabolic , adrenal , renal , hepatic , respiratory , inflammatory , infectious disease presence risk factor QTc prolongation history significant skin disease allergy , include allergy hypersensitivity excipients investigational medication TMC278 methadone Previous experience clinically significant hypersensitivity methadone hydrochloride Use disallow concomitant therapy 14 day prior first dose TMC278 recent donation blood plasma participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>TMC278-TiDP6-C121</keyword>
	<keyword>TMC278-C121</keyword>
	<keyword>open-label</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>methadone</keyword>
	<keyword>TMC278</keyword>
</DOC>